Back to Search
THIYAGU GANESAN, MD
MD
Pediatrics Physician
NPI: 1508204009Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
A140735(CA)
Research & Publications (20)
RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
PMID 16878154·Oncogene·2007
8-other
Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells.
PMID 16337592·Mol Cell·2005
8-other
Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.
PMID 16135466·J Clin Oncol·2005
3-trial
Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
PMID 15956976·Br J Cancer·2005
3-trial
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
PMID 15475440·Clin Cancer Res·2004
3-trial
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
PMID 15385119·Gynecol Oncol·2004
3-trial
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
PMID 15354209·Br J Cancer·2004
3-trial
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.
PMID 15162145·Br J Cancer·2004
3-trial
A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene.
PMID 15131034·Clin Cancer Res·2004
3-trial
Presumptive coding. A preliminary study of the aggregation of input diagnoses to determine their relevance to clinical governance and urological resourcing.
PMID 15008728·BJU Int·2004
4-observational
MSI-low, a real phenomenon which varies in frequency among cancer types.
PMID 14595750·J Pathol·2003
8-other
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.
PMID 14520440·Br J Cancer·2003
4-observational
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
PMID 12538455·Clin Cancer Res·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5730 PACKARD AVENUE, SUITE NO: 500
MARYSVILLE, CA 95993 - Phone
- (530) 749-3242
Quick Facts
- NPI
- 1508204009
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile